Additionally, the proposed coactivators, including p300, HATs, MAML, and SKIP [41], and corepressors, including CTBPs and SMRT [42], for mammalian Notch pathway reveal positive and negative transductivity sensitivities at both AML and MDS, respectively (Figure 8). This evidence concerns the gene EP300 and acute myeloid leukemia.